Vitiligo
Not recruitingStudy on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Belgium- Participants:18–64 years · 65+ years
- Substances:MK-6194
- Sponsor:Merck Sharp & Dohme LLC
Rare diseases
Investigational molecules
Locations
Back to Belgium1 245 clinical trials in Brugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
BelgiumStudy of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment
BelgiumStudy Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer
BelgiumStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
BelgiumStudy on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
BelgiumStudy on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years
BelgiumStudy Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy
BelgiumStudy of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors
BelgiumStudy of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
BelgiumStudy on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment
BelgiumStudy on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia
BelgiumStudy on the Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Researchers in Brugge are advancing prevention and treatment of bacterial infections and fungal diseases through vaccine and antimicrobial studies.
These trials aim to strengthen protection against serious infections and support public health in the region.
Investigators are testing innovative therapies to lower heart risk in patients with atherosclerosis, elevated lipoprotein(a), and amyloid‑related cardiomyopathy.
The goal is to reduce morbidity and mortality from heart disease, a leading health concern in Brugge.
Studies target gastrointestinal disorders, evaluating novel compounds for irritable bowel syndrome relief and ulcerative colitis remission.
Advances aim to enhance quality of life for individuals living with chronic digestive conditions.
A range of trials on hematologic malignancies are underway, seeking more effective regimens for lymphomas and acute leukemias.
These efforts aim to improve survival and reduce treatment toxicity for patients with blood cancers in the city.
Research includes autoimmune and immune‑mediated conditions, testing agents that restore immune balance such as in chronic graft‑versus‑host disease and Graves’ disease.
Outcomes may provide new options for patients whose immune systems attack their own tissues.
Trials focus on advanced prostate cancer, comparing targeted agents with standard chemotherapy to extend survival in metastatic castration‑resistant prostate cancer.
The aim is to offer men in Brugge more effective therapeutic choices when disease progresses.
Broad oncology programs explore innovative treatments for ovarian cancer and other gynecologic malignancies, including fallopian tube and peritoneal tumors.
These studies strive to improve response rates and long‑term outcomes for women affected by gynecologic malignancies in Brugge.
Tell us about your condition – we search every trial in Europe and connect you with the right site.